TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Seamos Activas: Increasing Physical Activity Among Latinas
Brief Summary: The overarching goal of this project is to develop a culturally congruent intervention to increase levels of physical activity among sedentary Latinas (i.e., Latina/Hispanic women). The first phase will involve culturally and linguistically modifying an existing evidenced-based intervention, founded on the Transtheoretical Model and Social Cognitive Theory, to target sedentary Latinas. Then, we will conduct a pilot randomized clinical trial to test whether the culturally-modified individually tailored intervention increases physical activity levels in comparison to standard care comprised of bilingual health education booklets.


Options:
A: Inclusion Criteria:

* 3rd-5th grade student enrolled in after-school program in San Francisco Unified School District

Exclusion Criteria:

* Uncontrolled asthma
* Unable to participate in moderate physical activity
B: Inclusion Criteria:

* African American (3 of 4 grandparents are of African Descent)
* Lives in designated census area
* No plans to move in the next two years
* Has no medical condition that would limit participation in moderate intensity exercise including life-threatening illness (e.g., immobile, severely disabled, or bed ridden)
* Available and able to participate in measures and intervention activities over the next 2 years

Exclusion Criteria:

* Extreme Blood Pressure and/or Blood Glucose levels
* Unable to take a brisk, 30-minute walk
C: Inclusion Criteria:

* regional Northern California KP employees

Exclusion Criteria:

* none
D: Inclusion Criteria:

* Sedentary (i.e., participating in moderate or vigorous physical activity two days per week or less for 30 minutes or less each day) women ages 18 to 65 who self-identify as Latina (or of a group defined as Hispanic/Latino by the Census Bureau) are eligible for participation

Exclusion Criteria:

* Exclusion criteria are history of coronary heart disease (history of myocardial infarction or symptoms of angina), diabetes, stroke, osteoarthritis, osteoporosis, orthopedic problems, or any other serious medical condition that would make physical activity unsafe. Other exclusion criteria will include individuals who report consuming three or more alcoholic drinks per day, current or planned pregnancy, planning to move from the area within the next six months, current suicidal ideation or psychosis, current clinical depression, hospitalization due to a psychiatric disorder in the past 3 years, BMI above 40, and/or taking medication that may impair physical activity tolerance or performance (e.g., beta blockers). Participants in the pilot study must also agree to be assigned to one of the two intervention conditions.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Functional Evaluation of a Follow on Formula Supplemented With Lactobacillus Salivarius CECT5713
Brief Summary: The aim of the trial is to evaluate safety of a follow on formula supplemented with Lactobacillus salivarius CECT5713. A randomized double blind placebo controlled trial was carried out. Eighty six months old children were recruited by the department of pediatrics of Hospital Univeristario San Cecilio. Children were divided in two groups that consumed a follow on formula supplemented or not with the probiotic strain during 6 months. Fecal samples were obtained at the recruitment, at 3 months and at the end of the trial. In addition revision by the pediatrician was performed once a month and possible adverse effects were recorded both by the pediatrician and by parents.


Options:
A: Inclusion Criteria:

* 6 months old children born at term
* written consent from parents

Exclusion Criteria:

* frequent gastrointestinal disorders (frequent diarrhoeas, constipation episodes, gastroesophageal reflux)
* gastrointestinal surgery
* cow's milk protein allergy
* metabolic diseases (diabetes or lactose intolerance)
* immune deficiency
* antibiotic treatment during the trial and/or recent (within the preceding 3 weeks)
B: Inclusion Criteria:

* Children hospitalized at the Department of Paediatrics, Children's Hospital Zagreb
* Age from 1 year to 18 years
* Signed informed consent by the parents

Exclusion Criteria:

* Immunodeficiency
* Infants from neonatal period until 1 year of age
* Re-hospitalisation (readmission in a hospital within one month)
* Receiving probiotic and /or prebiotic products prior to enrolment (2 weeks prior to hospitalization)
* Neoplasms
* Severe chronic diseases
* Hospitalization shorter than 3 days
C: Inclusion Criteria:

* Healthy six months old children

Exclusion Criteria:

* Lactose intolerance
* Cow's milk protein allergy
* Serious metabolic diseases
* Antibiotic treatment
* Serious gastrointestinal diseases
D: Inclusion Criteria:

* mother or father fo child with doctor diagnoses allergic disease

Exclusion Criteria:

* prematurity, major malformations

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Telephone Care Coordination for Smokers in Mental Health Clinics
Brief Summary: The purpose of this study is to evaluate whether a smoking cessation telephone care coordination program is effective and feasible in VA Mental Health Clinics.


Options:
A: Inclusion Criteria:

* Tobacco users calling the SNTQ to discuss his/her own tobacco behaviour.
* The client gives verbal consent to sign up for cessation support.
* The client return a registration form including a baseline questionnaire

Exclusion Criteria:

* Snuff cessation
B: Inclusion Criteria:

* Smokers who are referred from Mental Health Clinics in VA VISNs 1 and 3.
* Patients must have access to a telephone and a regular mailing address.

Exclusion Criteria:

* No access to a telephone
* no mailing address
* not receiving care from a VISN 1 or VISN 3 Mental Health provider
C: Inclusion Criteria:

* Hong Kong residents aged 18 or above
* Smoke at least 1 cigarette per day in the past 3 months
* Able to communicate in Cantonese
* Exhaled carbon monoxide (CO) 4 ppm or above, assessed by a validated CO smokerlyzer
* Have Intention to quit

Exclusion Criteria:

* Smokers who have difficulties (either physical or cognitive condition) to communicate
* Currently following other smoking cessation programs
D: Inclusion Criteria:

* intent-to-treat sedentary male and female smokers (intention to quit within the next 6 months) - - - smoke 6 or more cigarettes per day.
* Sedentary critieria: not purposeful physical activity for less than 20 minutes of vigorous intensity, or less than 60 minutes of moderate intensity physical activity per week, or less than 100 minutes of time spent walking per week.

Exclusion Criteria:

* pregnancy
* current substance abuse (e.g., alcohol, cocaine, or stimulants);
* current diagnosis or treatment of bipolar and psychotic disorder (e.g., use of Haldol, Thorazine).

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Telephone Care Coordination for Smokers in Mental Health Clinics
Brief Summary: The purpose of this study is to evaluate whether a smoking cessation telephone care coordination program is effective and feasible in VA Mental Health Clinics.


Options:
A: Inclusion Criteria:

* Must be 18 years of age or older.
* Must be a current smoker.
* Must receive primary care at one of the participating clinics.
* Must have had a PCP visit within the last month at a participating clinic.
* Must have a working phone number listed in Partner's database.
* Must report race /ethnicity as African American or Hispanic or live in a low-SES block group (a census block group with a median income of \< $65,000).
* Must speak English or Spanish.

Exclusion Criteria:

* Hearing impaired patients who cannot use the telephone.
B: Inclusion Criteria:

* Diagnostic and Statistical Manual of Mental Disorders IV criteria (DSM-IV) for diagnosis code 309.81 PTSD
* Willingness to participate
* Currently smoking 1 or more cigarettes per day

Exclusion Criteria:

* Use smokeless tobacco, pipes or cigars instead of cigarettes
* Have imminent risk of suicide or violence
* Have severe psychiatric symptoms or psychosocial instability likely to prevent participation in protocol (provider will assess appropriateness)
* Have clinically apparent gross cognitive impairment
* Unable to connect Health Buddy in home
C: Inclusion Criteria:

* Smokers who are referred from Mental Health Clinics in VA VISNs 1 and 3.
* Patients must have access to a telephone and a regular mailing address.

Exclusion Criteria:

* No access to a telephone
* no mailing address
* not receiving care from a VISN 1 or VISN 3 Mental Health provider
D: Inclusion Criteria:

* 18 years or older
* have smoked \>= 100 cigarettes lifetime
* describe themselves as every or some day smokers
* smoke at least 5 cigarettes/day
* own a cellphone with texting capability
* are able to give written informed consent

Exclusion Criteria:

* Inability to read or understand English
* currently receiving formal tobacco dependence treatment
* life-threatening or unstable medical, surgical, or psychobehavioral condition
* unable to provide at least one collateral contact
* live out-of-state
* leaving the ED against medical advice
* pregnant (self-report or urine testing), nursing, or trying to conceive.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: An Open-label, Observational Trial to Monitor the Incidence of Congenital Malformations in Infants of Women With an Ongoing Pregnancy After Controlled Ovarian Hyperstimulation Using Puregon® (recFSH)/Orgalutran® (Ganirelix) Followed by IVF/ICSI, or a Long Protocol With a GnRH Agonist as Historical Controls.
Brief Summary: The primary purpose of this study is to collect data on the incidence of congenital malformations in infants of women with an ongoing pregnancy after controlled ovarian stimulation with recombinant follicle stimulating hormone /ganirelix followed by in vitro fertilization (IVF) or intra cytoplasmatic sperm injection (ICSI), and to compare this incidence with that of a group of women who used a long protocol with a gonadotropin releasing hormone agonist as historical controls.


Options:
A: Inclusion Criteria:

* women of good physical and mental health
* under 37 years old, with regular menstrual cycles of 25-35 days
* normal basal FSH and LH levels
* BMI less than 30 kg/m2
* presence of both ovaries and intact uterus
* absence of polycystic ovaries
* endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases
* all patients signed a written informed consent form
* no patient had received any hormone therapy for at least 60 days preceding the study.
B: Inclusion Criteria:

* age \< 39
* follicle-stimulating hormone (FSH) \< 12
* gonadotropin dose 100-300IU

Exclusion Criteria:

* endometriosis
* known endocrine disorder
* blood analyzed in another laboratory
C: Inclusion Criteria:

* Puregon® (recFSH)/Orgalutran® group:

  * Women with a pregnancy of \>= 16 weeks after Puregon® /Orgalutran® treatment for IVF or ICSI and ET of fresh embryos. Treatment is defined as having had at least one injection of Orgalutran®.
  * Women between 18 and 39 years of age (inclusive) at the day of hCG.
  * Women who are able and willing to sign informed consent.

Controls

* Infants (gestational age \>=16 weeks) of women pregnant after COH using a GnRH agonist in a long protocol for IVF or ICSI and ET of fresh embryos.
* Infants of women between 18 and 39 years of age (inclusive) at the day of hCG.
* The most recent 1000 infants delivered prior to January 1, 2001.

Exclusion Criteria:

* None
D: Inclusion Criteria:

* All patients referred for infertility receiving their first IVF or IVF+ICSI treatment

Exclusion Criteria:

* Previous IVF or IVF+ICSI-treatment
* Uterine anomalies
* It is necessary to perform direct sperm aspiration from husband's/partner's testicles
* Allergy to one of the intervention products
* Patient is 40 years or above

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Brief Summary: This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.


Options:
A: Key Inclusion Criteria:

* Clinical diagnosis of SLE by ACR criteria.
* Active SLE disease.
* Autoantibody-positive.
* On stable SLE treatment regimen.

Key Exclusion Criteria:

* Pregnant or nursing
* Have received treatment with any B cell targeted therapy.
* Have received treatment with a biological investigational agent in the past year.
* Have received IV cyclophosphamide within 180 days of Day 0.
* Have severe lupus kidney disease.
* Have active central nervous system (CNS) lupus.
* Have required management of acute or chronic infections within the past 60 days.
* Have current drug or alcohol abuse or dependence.
* Have a historically positive test or test positive at screening for HIV, hepatitis B, or hepatitis C.
B: Inclusion Criteria:

* Have completed the HGS 1006-C1056 or HGS 1006-C1057 protocol through the Week 72 or Week 48 visits, respectively.

Exclusion Criteria:

* Have developed any other medical disease or condition that has made the patient unsuitable for this study in the opinion of their physician.
C: Inclusion Criteria:

* Have completed the HGS1006-C1056 protocol in the United States through Week 72 visit.
* Be able to receive 1st dose of belimumab for HGS 1006-c1066 four weeks after last dose in HGS1006-c1056.

Exclusion Criteria:

* Have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.
D: Inclusion Criteria:

1. At least 18 years of age.
2. Clinical diagnosis of Systemic Lupus Erythematosus (SLE) by ACR criteria.
3. Active SLE disease.
4. Autoantibody-positive.
5. On stable SLE treatment regimen which may include corticosteroids (for example, prednisone), antimalarial (for example, hydroxychloroquine) and/or immunosuppressants (for example, azathioprine, methotrexate, mycophenolate, etc.)

Exclusion Criteria:

1. Pregnant or nursing.
2. Have received treatment with any B cell targeted therapy (for example, rituximab or belimumab).
3. Have received treatment an investigational biological agent in the past year.
4. Have received intravenous (IV) cyclophosphamide within 90 days of Day 0.
5. Have severe active lupus kidney disease.
6. Have severe active central nervous system (CNS) lupus.
7. Have required management of acute or chronic infections within the past 60 days.
8. Have current drug or alcohol abuse or dependence.
9. Have a positive test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
10. Have a history of hypersensitivity reactions to contrast agents or biological medicines.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of a Low-Carbohydrate Mediterranean Diet or Low-Fat Diet in Newly-Diagnosed Type 2 Diabetic Patients
Brief Summary: The major environmental factors that increase the risk of type 2 diabetes, presumably in the setting of genetic risk, are overnutrition and a sedentary lifestyle, with consequent overweight and obesity. The high rate of weight regain has limited the role of lifestyle interventions as an effective means of controlling glycemia long term. The aims of the present study were: 1) To compare the effectiveness and safety of two nutritional protocols - namely low-carbohydrate Mediterranean diet or low-fat diet - in newly-diagnosed, drug-naive overweight patients with type 2 diabetes mellitus. The primary aim of the study was the effect on hemoglobin A1c levels; secondary aims were time to introduction of the first hypoglycemic agent, prevalence of the metabolic syndrome, percentage of patients meeting ADA goals for risk factors (HbA1c, blood pressure, LDL-cholesterol, percentage of patients with HbA1c \< 7%.


Options:
A: Postmenopausal women ages 50 to 79.
B: Inclusion Criteria:

* Having type 2 diabetes for at least three months prior to screening and treated with any antihyperglycemic medication
* A1C ≥7 %
* Consuming \<3 servings of dairy products per day
* On stable dose of diabetes, blood pressure or cholesterol medications for 3 months
* Body weight is within 10% of current weight over the last 6 months before starting the study

Exclusion Criteria:

* Pregnancy or lactation
* Lactose intolerance
* Allergy to milk or any of its components
* Use of orlistat
* History of pancreatitis
* History of gastric bypass surgery or sleeve gastrectomy
* Active malignancy
* History of recent cardiovascular event
* Having a heart pacemaker
* Enrollment in other studies that may affect study outcomes
C: Inclusion Criteria:

* Type 2 diabetes mellitus (ADA criteria)
* BMI (body mass index) \> 25 kg/M2
* Hemoglobin A1c (HbA1c) \< 11%; Blood pressure \< 160 (systolic) and 100 (diastolic) mm Hg
* Triglyceride levels \< 500 mg/dl.

Exclusion Criteria:

* Pregnancy or breast-feeding
* Previous use of insulin or oral antidiabetic drugs
* Investigational drug within the previous 3 months
* Use of agents affecting glycemic control (systemic steroids and weight loss drugs)
* Patients with history of alcohol or illicit drug abuse
* Patients with liver enzymes higher than three times the upper limit of normal
* Serum creatinine \> 1.4 mg/dl.
D: Men and women, age 25 and older who were generally healthy except for higher than optimal or mildly elevated blood pressure.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Association of Intravenous Ketamine With Thoracic Epidural Analgesia: Effects on Pain and Respiratory Function Following Thoracotomy.
Brief Summary: Thoracotomy for lung resection is deemed painful. Ketamine is now a renewed interest in preventing acute postoperative pain. A previous study performed in the service testing the association ketamine/morphine versus morphine PCA, postoperative, for patients who do not benefit from postoperative epidural thoracic surgery, has demonstrated a reduction of postoperative pain associated with a reduction of nocturnal arterial desaturation following surgery when ketamine was added to morphine.


Options:
A: Inclusion Criteria:

* Adult patients (≥ 18 years) with primary or recurrent single or double sided symptomatic but not incarcerated inguinal hernias with an elective hernia repair are included.
* No other interventions (i.e. umbilical hernia) are allowed.
* Written informed consent needs to be obtained.

Exclusion Criteria:

* Patients with legal incompetence,
* Pregnant and nursing women,
* Patients with presence or history of active malignancy or systemic diseases,
* Under immunosuppressive treatment,
* With systemic or severe local inflammation or infection,
* With wound healing disorders and with physical or mental incapacity, which makes it impossible to obtain informed consent are excluded.
* As pacemakers interfere with the electrical stimulation of the Pain Matcher® and vice versa patients with pacemakers or other implanted electrical devices were also excluded.
B: Inclusion Criteria:

* Patients with given inform consent, aged mor than 18 years, who undergo scheduled surgery of one of the following types: inguinal hernia (men), hysterectomy, thoracotomy (men).

Exclusion Criteria:

* Patients aged less than 18 years,
* Patients requiring reoperation because of surgical complications.
C: Inclusion Criteria:

* Subject between 18 and 85 years
* subject of both sexes
* subject operated in the service of thoracic surgery of a lobectomy by thoracotomie lateral or postlaterale subject
* subject operated in settled surgery

Exclusion Criteria:

* Against indication in the epidural insanity,
* confusionnel, patient psychotic
* treatment in the long price by medicine which can interfere on the pain (morphine, antidepressants, psychotropic treatment)
D: Inclusion Criteria:

* age \> 18 years
* all patients requiring a non-urgent caesarian done according to the Misgav-Ladach technique

Exclusion Criteria:

* Patients requiring very urgent caesarian
* allergic to levobupivacaïne
* with previous history of alcoholism or drug addiction
* with severe hypotension or an ischemic cardiopathy badly compensated or thyrotoxicoses
* treated with first generation of IMAO (monoamine oxidase inhibitor) or with anti-arrhytmia drugs with anesthesic activity

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Association of Intravenous Ketamine With Thoracic Epidural Analgesia: Effects on Pain and Respiratory Function Following Thoracotomy.
Brief Summary: Thoracotomy for lung resection is deemed painful. Ketamine is now a renewed interest in preventing acute postoperative pain. A previous study performed in the service testing the association ketamine/morphine versus morphine PCA, postoperative, for patients who do not benefit from postoperative epidural thoracic surgery, has demonstrated a reduction of postoperative pain associated with a reduction of nocturnal arterial desaturation following surgery when ketamine was added to morphine.


Options:
A: Inclusion Criteria:

* Patients 60 and older
* Competent to provide informed consent
* Undergoing major surgery (e.g., open cardiac surgery, open or thoracoscopic thoracic surgery, abdominal surgery, open urological surgery, open gynecological surgery, major orthopedic surgery, major vascular surgery including endovascular procedures, major ear, nose and throat surgery).

Exclusion Criteria:

* Patients with an allergy to ketamine
* Those in whom a significant elevation of blood pressure would constitute a serious hazard (e.g., pheochromocytoma, aortic dissection)
* Unable to provide informed consent
* Patients with drug misuse history (e.g., ketamine, cocaine, heroin, amphetamine, methamphetamine, MDMA, phencyclidine, lysergic acid, mescaline, psilocybin)
* Patients taking anti-psychotic medications (e.g., chlorpromazine, clozapine, olanzapine, risperidone, haloperidol, quetiapine, risperidone, paliperidone, amisulpride, sertindole)
* Patients with a weight outside the range 50 kg - 200 kg (110 lbs - 440 lbs)
B: Inclusion Criteria:

* Patients scheduled for robot-assisted thyroidectomy
* ASA I-III

Exclusion Criteria:

* Patients with renal dysfunction
* Patients with hepatic dysfunction
* Patients with neurologic dysfunction
* Patients with the history of drug addiction
* Patients with chronic pain
* Patients who are allergic to ketamine
* Patients with increased ocular or intracranial pressure
* Patients with the risk of aspiration
C: Inclusion Criteria:

* Subject between 18 and 85 years
* subject of both sexes
* subject operated in the service of thoracic surgery of a lobectomy by thoracotomie lateral or postlaterale subject
* subject operated in settled surgery

Exclusion Criteria:

* Against indication in the epidural insanity,
* confusionnel, patient psychotic
* treatment in the long price by medicine which can interfere on the pain (morphine, antidepressants, psychotropic treatment)
D: Inclusion Criteria:

* 18 Years to 65 Years ASA I and II Accepts healthy volunteers.

Exclusion Criteria:

alcohol or illicit drugs, H2 inhibitors, opioids, or calcium-channel blockers within the last 10 days chronic pain, myocardial ischemia, psychiatric diseases.

Answer: C